Article
Oncology
Sharyn Katz, Leonid Roshkovan, Ian Berger, Joseph S. Friedberg, Evan W. Alley, Charles B. Simone, Andrew R. Haas, Keith A. Cengel, Daniel H. Sterman, Steven M. Albelda
Summary: Serum levels of SMRP and fibulin-3 show correlation with tumor volume in malignant pleural mesothelioma, but are not useful in predicting tumor response in immunogene therapy trial.
Article
Oncology
Nicolai B. Palstrom, Martin Overgaard, Peter Licht, Hans C. Beck
Summary: Proteins found in pleural effusion can serve as biomarkers for the diagnosis of malignant pleural mesothelioma (MPM). The identification of these proteins can significantly improve the accuracy of MPM diagnosis. Therefore, analyzing the protein composition of pleural effusion can lead to new diagnostic methods for MPM.
Review
Oncology
Laura Castelletti, Dannel Yeo, Nico van Zandwijk, John E. J. Rasko
Summary: Malignant mesothelioma is a challenging tumor with limited treatment options. CAR-T cell therapy targeting the antigen mesothelin shows promise, but efficacy is currently modest. Overcoming the challenges posed by the MM tumor microenvironment and finding more effective treatment strategies will be the focus of future research.
BIOMARKER RESEARCH
(2021)
Review
Oncology
Zishuo I. Hu, Azam Ghafoor, Manjistha Sengupta, Raffit Hassan
Summary: Malignant mesothelioma is an aggressive cancer with poor prognosis and limited treatment options. The recent approval of nivolumab plus ipilimumab as frontline treatment for patients with pleural mesothelioma represents a significant milestone in the management of this disease, highlighting the emerging use of immunotherapy and mesothelin-targeted therapies for advanced cases.
Review
Oncology
Ram Kumar Sahu, Sakina Ruhi, Ashok Kumar Jeppu, Husni Ahmed Al-Goshae, Ayesha Syed, Sanjay Nagdev, Retno Widyowati, Wiwied Ekasari, Jiyauddin Khan, Bedanta Bhattacharjee, Manoj Goyal, Sankha Bhattacharya, Rajendra K. Jangde
Summary: Malignant mesothelioma is a rare and aggressive tumor that develops in the mesothelium layer and is highly resistant to standard treatments. Despite the worldwide ban on asbestos, the prevalence of mesothelioma continues to increase. Diagnosis and treatment of mesothelioma are challenging, and current treatments are largely ineffective. However, recent advances in understanding the genetics and molecular pathophysiology of mesothelioma have been made, particularly in the hippo signaling pathway.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Paul Stockhammer, Hannah Baumeister, Till Ploenes, Francesco Bonella, Dirk Theegarten, Balazs Dome, Christine Pirker, Walter Berger, Luca Hegedues, Marcell Baranyi, Martin Schuler, Sophie Deshayes, Servet Bolukbas, Clemens Aigner, Christophe Blanquart, Balazs Hegedues
Summary: This study is the first to demonstrate KL-6 as a potential novel liquid-based diagnostic and prognostic biomarker in pleural mesothelioma, which may help improve patients' survival rates.
Article
Medicine, General & Internal
Federica Grosso, Matilde Mannucci, Francesca Ugo, Paola Ferro, Maurizio Cassinari, Antonella Vigani, Antonina Maria De Angelis, Sara Delfanti, Michela Lia, Roberto Guaschino, Stefano Barbero, Silvio Roncella, Ugo Giannoni, Marinella Bertolotti, Maria Pia Pistillo, Vincenzo Fontana
Summary: This pilot study aimed to evaluate the correlation between soluble mesothelin-related peptide (SMRP) levels and modified RECIST (mRECIST) score over time in pleural mesothelioma (PM) patients. The results indicated a statistically significant correlation between SMRP and mRECIST score, suggesting SMRP measurement could be considered as an adjunct for monitoring PM patients. Further investigation is warranted to validate these findings.
Article
Cell Biology
Gerard J. Chu, Anthony Linton, Steven Kao, Sonja Klebe, Stephen Adelstein, Dannel Yeo, John E. J. Rasko, Wendy A. Cooper
Summary: This study aimed to assess the intensity and distribution of MSLN immunostaining in mesothelioma and determine its prognostic value. The results showed that MSLN expression was more heterogeneous in epithelioid mesothelioma, suggesting the need for immunohistochemical assessment to stratify and assess patient suitability for personalized therapies targeting MESOTELIN.
Article
Multidisciplinary Sciences
Carmina Jimenez-Ramirez, Daniel Gilbert Weber, Guadalupe Aguilar-Madrid, Alexander Brik, Cuauhtemoc Arturo Juarez-Perez, Swaantje Casjens, Irina Raiko, Thomas Bruning, Georg Johnen, Alejandro Cabello-Lopez
Summary: This study examines the behavior and diagnostic value of miR-103a-3p in Mexican population with malignant pleural mesothelioma (MPM). The study finds that miR-103a-3p levels are correlated with several characteristics, but adding it to mesothelin and calretinin does not improve the diagnostic performance for MPM.
Review
Respiratory System
Eline Schillebeeckx, Jan P. van Meerbeeck, Kevin Lamote
Summary: Malignant pleural mesothelioma is typically diagnosed in late stages with poor prognosis, and non-invasive diagnostic biomarkers show potential but lack consensus on clinical use and validation methods.
EUROPEAN RESPIRATORY REVIEW
(2021)
Review
Oncology
Alex Dipper, Nick Maskell, Anna Bibby
Summary: Malignant pleural mesothelioma (MPM) presents diagnostic challenges, with ancillary diagnostic tests such as immunocytochemical markers, molecular techniques, diagnostic biomarkers, and imaging discussed in cases where histological samples are unavailable or inconclusive. While no single adjunctive test has the sensitivity and specificity to diagnose MPM in isolation, correlation of pleural fluid cytology with radiology and biomarkers can help make an MDT-consensus diagnosis when invasive tests are not feasible.
Article
Biochemistry & Molecular Biology
Dilek Yonar, Mete Severcan, Rafig Gurbanov, Abdulsamet Sandal, Ulku Yilmaz, Salih Emri, Feride Severcan
Summary: This study successfully developed a new approach for the characterization and diagnosis of malignant pleural mesothelioma (MPM) among lung diseases using Fourier transform infrared spectroscopy (FTIR) coupled with multivariate analysis. The results showed that the MPM group could be successfully differentiated from healthy, benign exudative effusion, and lung cancer groups based on the changes in lipid biosynthesis and nucleic acids levels in the malignant serum samples.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2022)
Article
Immunology
Aline Nery Qualiotto, Camila Machado Baldavira, Marcelo Balancin, Alexandre Ab'Saber, Teresa Takagaki, Vera Luiza Capelozzi
Summary: The study confirmed the importance of mesothelin in malignant pleural mesothelioma and explored its relationship with the immune landscape of the tumor microenvironment. Mesothelin expression associated with the TME immune landscape predicts the risk of death for MPM patients, indicating it could be a new target for immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Vincenzo Fontana, Maria Pia Pistillo, Antonella Vigani, Pier Aldo Canessa, Giovanni Berisso, Ugo Giannoni, Paola Ferro, Maria Cristiana Franceschini, Roberta Carosio, Marika Tonarelli, Paolo Dessanti, Silvio Roncella
Summary: This study highlights the prognostic value of serum soluble mesothelin-related protein (Se-SMRP) in patients with malignant pleural mesothelioma (MPM), showing an increasing trend in death rate ratios (RR) with higher Se-SMRP levels. The study provided evidence in favor of the prognostic significance of Se-SMRP in MPM patients.
Review
Oncology
Dannel Yeo, Laura Castelletti, Nico van Zandwijk, John E. J. Rasko
Summary: Mesothelioma is a deadly cancer with limited treatment options. Mesothelin is overexpressed in mesothelioma but not in normal cells, making it a potential biomarker and therapeutic target. Research on the diagnostic and therapeutic value of mesothelin in mesothelioma patients is ongoing to improve patient outcomes.
Editorial Material
Respiratory System
Y. C. Gary Lee, Jenette Creaney
Article
Oncology
Alistair M. Cook, Alison McDonnell, Michael J. Millward, Jenette Creaney, Arman Hasani, Michelle McMullen, Tarek Meniawy, Bruce W. S. Robinson, Richard a Lake, Anna K. Nowak
Summary: The study aimed to determine optimal dosing and scheduling of cyclophosphamide alongside pemetrexed-based chemotherapy to deplete regulatory T-cells in mesothelioma or non-small-cell lung cancer patients. However, the results showed that the specific Treg depletion seen with single-agent cyclophosphamide was not observed during pemetrexed-based chemotherapy, indicating poor evidence for the use of cyclophosphamide as an immunotherapeutic in combination with chemotherapy. Additionally, some patients had to discontinue cyclophosphamide due to toxicity.
EXPERT REVIEW OF ANTICANCER THERAPY
(2021)
Review
Oncology
Linda Ye, Jenette Creaney, Alec Redwood, Bruce Robinson
Summary: Neoantigens are unique mutant peptides in tumors that can elicit T-cell-mediated immune responses and are potential targets for personalized cancer therapies. Immunotherapy based on neoantigens in lung cancer shows promising prospects and opportunities for clinical applications.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
I. M. Dick, Y. C. G. Lee, H. M. Cheah, A. Miranda, B. W. S. Robinson, J. Creaney
Summary: This study demonstrates that pleural effusions rich in a range of soluble factors are associated with poor prognosis in mesothelioma patients. These findings will enhance our ability to prognosticate outcomes in mesothelioma patients.
Article
Cell Biology
Amber Louw, Y. C. Gary Lee, Nathan Acott, Jenette Creaney, Chris Vliet, Siaw Ming Chai
Summary: The study assessed the utility of BAP1 immunohistochemistry in fluid samples for diagnosing malignant pleural mesothelioma. Results showed that loss of BAP1 was highly specific for malignancy, aiding in the diagnosis.
Article
Oncology
Amber Louw, Chris van Vliet, Joanne Peverall, Shane Colkers, Nathan Acott, Jenette Creaney, Y. C. Gary Lee, Siaw Ming Chai
Summary: This study found that detectable abnormalities of BAP1 and CDKN2A were present in pleural fluid specimens before the development of mesothelioma, suggesting a possible cytological equivalent for mesothelioma in situ.
CANCER CYTOPATHOLOGY
(2022)
Review
Oncology
Alec J. Redwood, Ian M. Dick, Jenette Creaney, Bruce W. S. Robinson
Summary: The process of tumorigenesis results in genetic changes in tumor cells that have potential to serve as tumor-specific immune targets when expressed. Neoantigen vaccines, harnessing this immunogenicity, have shown efficacy in preclinical models and are now in clinical trials. The challenges in the personalized neoantigen vaccine field include identifying targetable antigens and addressing preexisting immunosuppression, particularly T-cell exhaustion, for the development of effective cancer vaccines.
Article
Oncology
Amber Louw, Vasiliki Panou, Weronika Maria Szejniuk, Christos Meristoudis, Siaw Ming Chai, Chris van Vliet, Y. C. Gary Lee, Ian M. Dick, Tina Firth, Louise Andersen Lynggaard, Azadeh Birbaneh Asghari, Mogens Vyberg, Johnni Hansen, Jenette Creaney, Oluf Dimitri Roe
Summary: This study aimed to evaluate the impact of tumor BAP1 status on survival prediction in patients with pleural mesothelioma receiving first-line combination chemotherapy. The study found that BAP1 loss was an independent predictor of survival, and patients with BAP1 loss had longer survival after chemotherapy.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Genetics & Heredity
Jenette Creaney, Ann-Marie Patch, Venkateswar Addala, Sophie A. Sneddon, Katia Nones, Ian M. Dick, Y. C. Gary Lee, Felicity Newell, Ebony J. Rouse, Marjan M. Naeini, Olga Kondrashova, Vanessa Lakis, Apostolos Nakas, David Waller, Annabel Sharkey, Pamela Mukhopadhyay, Stephen H. Kazakoff, Lambros T. Koufariotis, Aimee L. Davidson, Priya Ramarao-Milne, Oliver Holmes, Qinying Xu, Conrad Leonard, Scott Wood, Sean M. Grimmond, Raphael Bueno, Dean A. Fennell, John Pearson, Bruce W. Robinson, Nicola Waddell
Summary: This study analyzed the genomic and immune features of malignant pleural mesothelioma (MPM) samples and identified driver genes, mutational signatures, and the tumor immune environment associated with MPM. The findings suggest that accounting for genomic and immune microenvironment status may influence future therapeutic planning.
Review
Pharmacology & Pharmacy
Bruce W. S. Robinson, Alec J. Redwood, Jenette Creaney
Summary: Researchers have used asbestos-induced mouse models of mesothelioma to study this rare and fatal tumor type. These models have led to significant advancements in mesothelioma treatment, including improved response rates through clinical trials. In the future, these mouse models will continue to play a key role in the success of mesothelioma immunotherapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Letter
Oncology
Oluf Dimitri Roe, Jenette Creaney
JOURNAL OF THORACIC ONCOLOGY
(2022)
Article
Oncology
P. Ramarao-Milne, O. Kondrashova, A. -M. Patch, K. Nones, L. T. Koufariotis, F. Newell, V. Addala, V. Lakis, O. Holmes, C. Leonard, S. Wood, Q. Xu, P. Mukhopadhyay, M. M. Naeini, D. Steinfort, J. P. Williamson, M. Bint, C. Pahoff, P. T. Nguyen, S. Twaddell, D. Arnold, C. Grainge, F. Basirzadeh, D. Fielding, A. J. Dalley, H. Chittoory, P. T. Simpson, L. G. Aoude, V. F. Bonazzi, K. Patel, A. P. Barbour, D. A. Fennell, B. W. Robinson, J. Creaney, G. Hollway, J. V. Pearson, N. Waddell
Summary: This study explored drug repurposing opportunities using the Cancer Genome Interpreter and whole-genome sequencing. The ability of different sequencing methods, including whole-exome sequencing and comprehensive sequencing panels, to detect actionable mutations, tumor mutation burden, and microsatellite instability was compared. The results revealed shared biomarkers among different solid tumor types, with comprehensive panels identifying the majority of actionable mutations and whole-genome sequencing detecting more candidate actionable mutations.
Article
Oncology
Faith Chang, Synat Keam, Tracy Seymour Hoang, Jenette Creaney, Suki Gill, Anna K. Nowak, Martin Ebert, Alistair M. Cook
Summary: This study characterizes the dose- and time-dependent changes in immune marker expression of commonly studied mesothelioma cell lines following radiation, providing insights for future studies on optimal dosing and scheduling of combined radiotherapy and immune checkpoint inhibition for mesothelioma.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Venkateswar Addala, Felicity Newell, John V. Pearson, Alec Redwood, Bruce W. Robinson, Jenette Creaney, Nicola Waddell
Summary: Cancer immunogenomics is an emerging field that combines genomics and immunology to better understand and improve cancer immunotherapy. The use of large-scale genomic collaborations and advanced sequencing techniques has allowed researchers to identify clinically actionable alterations and predictive biomarkers in various types of cancer. Computational approaches and machine learning algorithms have been developed to analyze sequencing data and provide clinically useful information. However, there is still a need to fully understand the potential and limitations of these approaches in improving patient outcomes.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Linda Ye, Ian Dick, Peter Chiang, Tina Firth, Jenette Creaney, Bruce Ws Robinson, Alec Redwood
JOURNAL OF CLINICAL ONCOLOGY
(2022)